| Xander Hsu Buenafe, MD | |
|
411 E Market St, Akron, OH 44304-1542 | |
| (330) 252-0600 | |
| Not Available |
| Full Name | Xander Hsu Buenafe |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 411 E Market St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598916256 | NPI | - | NPPES |
| 09014144 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 22233 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Xander Hsu Buenafe, MD 411 E Market St, Akron, OH 44304-1542 Ph: (330) 252-0600 | Xander Hsu Buenafe, MD 411 E Market St, Akron, OH 44304-1542 Ph: (330) 252-0600 |
News Archive
The American Medical Association (AMA) today announced a new online tool designed to help physician practices prepare for billing and payment audits by insurers and federal contractors. The AMA's Practice Analysis Tools for Healthcare (AMA PATH™) puts self-auditing tools in the hands of physicians, allowing them to develop and evaluate fee schedules and billing safeguards without hiring an expensive consultant.
Viral Genetics has identified two key peptides involved in its thymus nuclear protein or "TNP" technology currently under development for the treatment of HIV/AIDS.
Reflecting its drive to provide innovative solutions to the genomics community, Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system.
For the first time, researchers have identified a reliable marker (PDGFRβ) to detect carcinoma-associated fibroblasts (cells within the tumor that encourage growth and metastasis) (CAFs) in oral cancer tissues. With this discovery, anti-PDGFRβ treatment could soon be combined with existing tumor treatments to provide a more effective cancer therapy.
New research published in the Journal of Analytical Toxicology shows how fingerprint-based drug screening can not only screen for the presence, or absence, of four classes of drugs of abuse, but that the technology also works when used by UK coroners to detect drugs in the sweat of fingerprint samples gathered from deceased individuals.
› Verified 8 days ago
Dr. Michael A Pelini, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Nephrology Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |